The estimated Net Worth of Malcolm Salter is at least 306 千$ dollars as of 17 December 2021. Malcolm Salter owns over 755 units of C4 Therapeutics stock worth over 65,712$ and over the last 4 years Malcolm sold CCCC stock worth over 239,788$.
Sign up
Malcolm Salter CCCC stock SEC Form 4 insiders trading
Malcolm has made over 9 trades of the C4 Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Malcolm sold 755 units of CCCC stock worth 22,839$ on 17 December 2021.
The largest trade Malcolm's ever made was buying 1,315 units of C4 Therapeutics stock on 6 October 2020 worth over 24,985$. On average, Malcolm trades about 409 units every 24 days since 2020. As of 17 December 2021 Malcolm still owns at least 10,952 units of C4 Therapeutics stock.
You can see the complete history of Malcolm Salter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Malcolm Salter's mailing address?
Malcolm's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.
Insiders trading at C4 Therapeutics
Over the last 4 years, insiders at C4 Therapeutics have traded over 12,678,122$ worth of C4 Therapeutics stock and bought 27,275 units worth 336,287$ . The most active insiders traders include Marc A Cohen、Alain J Cohen、Elena Prokupets. On average, C4 Therapeutics executives and independent directors trade stock every 17 days with the average trade being worth of 56,874$. The most recent stock trade was executed by Andrew Hirsch on 30 August 2023, trading 7,500 units of CCCC stock currently worth 45,000$.
What does C4 Therapeutics do?
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
What does C4 Therapeutics's logo look like?
Complete history of Malcolm Salter stock trades at C4 Therapeutics
C4 Therapeutics executives and stock owners
C4 Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Adam S. Crystal M.D., Ph.D.,
Chief Medical Officer -
Andrew J. Hirsch,
CEO, Pres & Director -
Marc A. Cohen,
Co-Founder, Exec. Chairman & Sec. -
Dr. Kenneth C. Anderson M.D., Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Kristina Zambouras,
Director of HR -
Jolie M. Siegel J.D.,
Chief Legal Officer -
Kendra Adams,
Sr. VP of Communications & Investor Relations -
Dr. Stewart Fisher,
Chief Scientific Officer -
Lauren White,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Adam Crystal,
Chief Medical Officer -
Jolie Siegel,
Chief Legal Officer -
Mark Mossler,
Chief Accounting Officer -
Stephen Fawell,
Director -
Laura Jean Wahlberg,
VP of Finance Corp Controller -
Leonard Reyno,
Chief Medical Officer -
Glenn Dubin,
Director -
Marc A Cohen,
Director -
Lauren White,
Chief Financial Officer -
Elena Prokupets,
Director -
Bruce Downey,
Director -
Malcolm Salter,
Director -
Kenneth Carl Anderson,
Director -
William Mckee,
Chief Financial Officer -
Stewart Fisher,
Chief Scientific Officer -
Alain J Cohen,
Director -
Donna Roy Grogan,
Director -
Laura Bessen,
Director -
Utpal Koppikar,
Director -
Scott N Boyle,
Chief Business Officer -
Kelly Schick,
Chief People Officer -
Owen Hughes,
Director -
Ronald Harold Wilfred Cooper,
Director